CESCA THERAPEUTICS INC. (65) | Note Agreements (9)
Recent Contracts
-
Amendment No. 2 to Second Amended and Restated Convertible Promissory Note, dated March 6, 2023, between ThermoGenesis Holdings, Inc. and Boyalife Group Inc
(Filed With SEC on March 10, 2023)
-
Amendment No. 3 to Convertible Promissory Note, dated January 31, 2023, between ThermoGenesis Holdings, Inc. and Orbrex (USA) Co. Limited
(Filed With SEC on February 6, 2023)
-
Amendment No. 2 to Convertible Promissory Note, dated July 25, 2022, between ThermoGenesis Holdings, Inc. and Orbrex (USA) Co. Limited
(Filed With SEC on July 28, 2022)
-
Amendment No. 1 to Second Amended and Restated Convertible Promissory Note, dated March 4, 2022, between ThermoGenesis Holdings, Inc. and Boyalife Asset Holding II, Inc
(Filed With SEC on March 8, 2022)
-
Amendment No. 1, dated July 23, 2019, to the Convertible Promissory Note, dated January 29, 2019 between Cesca therapeutics Inc. and Orbrex USA Co
(Filed With SEC on November 19, 2019)
-
Amendment No. 1 to the Convertible Promissory Note, Dated July 23, 2019 between Cesca therapeutics Inc. and Orbrex USA Co
(Filed With SEC on August 13, 2019)
-
Form of Note
(Filed With SEC on July 29, 2019)
-
Amendment No. 1 to the Convertible Note Agreement dated as of July 23, 2019, between Cesca Therapeutics Inc. and Orbrex USA Co
(Filed With SEC on July 29, 2019)
-
Form of Note
(Filed With SEC on January 31, 2019)
